Pfizer Completes Acquisition of Vicuron Pharmaceuticals
Pfizer Inc completed its acquisition of Vicuron Pharmaceuticals Inc., a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. In connection with the closing, shares of Vicuron common stock have been delisted from the Nasdaq and Italy's Nuovo Mercato stock exchanges.
Through the transaction, Pfizer has acquired two new product candidates currently under review at the U.S. Food and Drug Administration (FDA): anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The addition of these product candidates broadens Pfizer's presence in anti-infectives where the company has a long history of providing patients and physicians with life-saving medicines.
Other news from the department business & finance
